Sotiria C. Apostolopoulou^1,*, Stella Brili², Eftihia Sbarouni³, Dimitris Tousoulis², Konstantinos Toutouzas²

Congenital Heart Disease, Vol.15, No.5, pp. 369-375, 2020, DOI:10.32604/CHD.2020.012092 - 23 September 2020

Abstract Objective: Acquired coronary artery disease, initially thought to rarely affect survivors of congenital heart disease, is increasingly recognized in this population, as these patients grow in age and numbers in the recent era. This study reports our experience with coronary artery disease in adults with congenital heart disease and discusses treatment issues and the existing literature. Methods: Retrospective review of all charts of adults with congenital heart disease and acquired coronary artery disease was performed. Patients’ clinical characteristics, diagnosis, risk factors, noninvasive and invasive imaging and management data were recorded. Results: Coronary artery disease was diagnosed at… More >

Alexander C. Egbe, Sindhura Ananthaneni, Raja Jadav, Srikanth Kothapalli, Charanjit S. Rihal, Muhammad Masood, Mounika Angirekula, Maria Najam, Numra Bajwa, Karim Tarek, Jessey Matthew, Heidi M. Connolly

Congenital Heart Disease, Vol.14, No.3, pp. 491-497, 2019, DOI:10.1111/chd.12782

Abstract Background: There are limited data about outcomes of coronary artery disease (CAD) in adults with repaired tetralogy of Fallot (TOF). The purpose of this study was to describe the prevalence and treatment of CAD in adults with TOF, and the impact of CAD on long‐term survival.
Methods: Retrospective review of MACHD database for adults with repaired TOF who underwent aortic root/selective coronary angiogram, 1990‐2017. Patients were categorized into three groups: (1) No CAD defined as normal coronary angiogram; (2) Mild CAD defined as ≤50% stenosis in all vessels; and, (3) Significant CAD defined as >50% stenosis in… More >

Shengxian Tu^1,*

Molecular & Cellular Biomechanics, Vol.16, Suppl.1, pp. 15-16, 2019, DOI:10.32604/mcb.2019.05704

Abstract Coronary artery disease (CAD) is the leading cause of mortality and morbidity worldwide. It is the disease of the blood vessels supplying the heart muscle. The fatty plaques built within the walls of the coronary arteries might rupture, creating a thrombus, thereby blocking the entire flow through the vessel, which is followed by a heart attack. Patients who suffer from CAD with documented ischemia are predominately sent to the catheterization laboratory for an invasive procedure (PCI, or percutaneous coronary intervention) to open the vessel by the placement of a “stent” as a scaffolding device to… More >

Bartosz Hudzik¹, Janusz Szkodzinski¹, Aleksander Danikiewicz², Wojciech Romanowski², Andrzej Lekston¹, Lech Polonski¹, Barbara Zubelewicz-Szkodzinska²

European Cytokine Network, Vol.21, No.2, pp. 129-135, 2010, DOI:10.1684/ecn.2010.0189

Abstract Background. Contrast media are being widely applied for both diagnostic and therapeutic purposes. This has resulted in increasing incidence of contrast-induced nephropathy (CIN). Methods. We aimed to investigate the value of baseline serum IL-6 concentrations in predicting CIN before the rise of serum creatinine (SCr) in patients undergoing percutaneous coronary intervention. Seventy four Caucasian patients were enrolled. CIN was defined as an increase in SCr concentration of more than 44 μmol/L, or a 25% increase above baseline within 48 hours after contrast administration. Results. CIN developed in 16 out of 74 patients (21.6%). The median… More >

Bartosz Hudzik¹, Janusz Szkodzinski¹, Aleksander Danikiewicz², Krzysztof Wilczek¹, Wojciech Romanowski², Andrzej Lekston¹, Lech Polonski¹, Barbara Zubelewicz-Szkodzinska²

European Cytokine Network, Vol.21, No.4, pp. 257-263, 2010, DOI:10.1684/ecn.2010.0213

Abstract Background. Dual antiplatelet therapy (aspirin plus clopidogrel) is recommended in patients undergoing percutaneous coronary intervention (PCI). Treatment with proton pump inhibitors (PPIs) decreases bleeding rate. Alarming reports have been made that PPIs may decrease the antiplatelet activity of clopidogrel. We sought to determine whether levels of interleukin-6 (IL-6) and transforming growth factor-β1 (TGF-β1) might help distinguish individuals at risk for adverse events. Methods. Thirty-eight patients on aspirin and clopidogrel were enrolled and divided into two groups: group 1 [patients receiving omeprazole (n = 18)] and group 2 [patients not receiving omeprazole (n = 20)]. Patients… More >